	US 12,281,362 B2
	Diagnostic tools and treatments for clear cell renal cell carcinoma
Maria Franciszka Czyzyk-Krzeska, Cincinnati, OH (US); Julio Alberto Landero Figueroa, Cincinnati, OH (US); Jarek Meller, Cincinnati, OH (US); David Plas, Cincinnati, OH (US); Shuchi Gulati, Cincinnati, OH (US); Bhargav Vemuri, Mason, OH (US); and John Thomas Cunningham, IV, Maineville, OH (US)
Assigned to University of Cincinnati, Cincinnati, OH (US)
Filed by University of Cincinnati, Cincinnati, OH (US)
Filed on May 21, 2021, as Appl. No. 17/327,100.
Claims priority of provisional application 63/110,042, filed on Nov. 5, 2020.
Prior Publication US 2022/0136059 A1, May 5, 2022
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)

CPC C12Q 1/6886 (2013.01) [G01N 33/57438 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/90216 (2013.01)]

9 Claims

1. A method of diagnosing an elevated risk of recurrence of clear cell renal cell carcinoma in a subject and treating the subject for clear cell renal cell carcinoma, comprising:

a. detecting and quantifying total copper content and Cu-COX complex in a sample of kidney tumor tissue or kidney tumor biopsy from said subject;

b. diagnosing an elevated risk of recurrence of clear cell renal cell carcinoma for a subject with:

i. a level of Cu-COX complex identified at a molecular mass range between 500 kDa-250 kDa is higher than 0.45 ng g⁻¹expressed as copper concentration; or

ii. the copper content at a molecular mass fraction between 500 kDa-250 kDa is ≥20% of the total copper in the sample; and

c. treating the subject diagnosed with an elevated risk of recurrence of clear cell renal cell carcinoma by administering a therapeutically effective amount of mitochondrial respiratory complex inhibitors, angiogenic inhibitors, inhibitors of the mTOR pathway, immune checkpoint inhibitors, mitoriboscins, inhibitors of mitoribosomes or combinations thereof to the subject.